english.prescrire.org > Spotlight > 100 most recent > Pregnancy and "disease-modifying" drugs for multiple sclerosis: what are the consequences for the unborn child?

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Pregnancy and "disease-modifying" drugs for multiple sclerosis: what are the consequences for the unborn child?

 Adverse effects  Multiple sclerosis is a disease of the central nervous system that usually follows a relapsing-remitting course. It often affects women and generally starts between the ages of 20 and 40 years. As of 2025, what is known about the consequences for the unborn child of exposure to the main disease-modifying drugs currently authorised in France for use in pregnant women with multiple sclerosis? This article reviews the main data we identified through our literature search. 
Full article available for download by subscribers

 ©Prescrire 1 December 2025

Source: "Pregnancy and 'disease-modifying' drugs for multiple sclerosis: what are the consequences for the unborn child?" Prescrire Int 2025; 34 (276): 297-302. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Multiple sclerosis:
beware of genotoxic drugs,
in women and men"
Prescrire Int 2025;
34 (276): 300-301.
 
"Towards better patient care:
drugs to avoid in 2025"
Prescrire Int 2025;
34 (267): 52-55 
(full version: 11 pages)
FREE